TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Blood
; 125(6): 915-23, 2015 Feb 05.
Article
in En
| MEDLINE
| ID: mdl-25519749
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperazines
/
Pyrimidines
/
Benzamides
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Protein Kinase Inhibitors
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood
Year:
2015
Document type:
Article
Country of publication:
United States